TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05045313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin sodium tablets
Description: Drug: Warfarin sodium, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Description: Drug: Digoxin, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid tablets
Description: Drug: Probenecid, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral
Study: NCT04628572

Intervention type: DRUG
Intervention: Ceftazidime-avibactam
Description: Non-Interventional Study
Study: NCT04630080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp cooling
Description: Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
Study: NCT06010888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib+mFOLFOX6/FOLFIRI
Description: Fruquintinib: 4mg po qd, d1-d21, q4w with mFOLFOX6/FOLFIRI (standard)
Study: NCT06226636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: salt
Description: After ≥8 hr overnight fasting, participants will be required to ingest 780 mg of sodium (2 g salt) and BP measured every 10 minutes for 2 hours to determine IPROS. For SSBP, Participants are put on low salt (50 mmol Na/day) followed by seven days of high salt diet (250 mmol Na/day). Participants' mean arterial pressure (MAP) difference between low- and high-salt diet will be used to define salt sensitivity (MAP≥8 mmHg) and salt resistance (MAP≤5 mmHg).
Study: NCT04941924

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraductal Radio-Frequency Ablation
Description: The electrode employed in this study is the STARmed ELRA™ (Endo Luminal Radiofrequency Ablation) electrode; this is a CE marked device. The selected electrode will be connected to the VIVA™ Combo generator (also a CE marked device) and advanced over the guide wire.~The power of the generator should be set at either 7 or 10 W depending on the electrode used per manufacturer instructions. An ablation should then be applied at a temperature of 70 to 80℃ for 2 minutes. For longer length strictures or stent occlusions, the RFA probe is withdrawn from proximal to distal in a step by step fashion in respect to the access method used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary Stent Placement
Description: Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biliary Stent Placement
Description: Taewoong Niti-S™ LCD Biliary stents (CE marked uncovered self-expanding metal stents) placed according to standard local practice.
Study: NCT06281431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echogenic nerve block needle
Description: A 22G 8-cm echogenic nerve block needle (LEAPMED, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The spread of the medication will be assessed through short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the incidence of punctures, and any associated complications are all meticulously appraised.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-echogenic nerve block needle
Description: A 22G 8-cm thin wall low bottom nerve block needle (KDL, CHINA) is selected for the procedure, administered under ultrasound guidance. Subsequently, a volume of 20 ml 0.375% ropivacaine is injected at the needle's tip for analgesic effect. The distribution of the medication will be assessed using short- and long-axis imaging perspectives. Following this, evaluations are conducted to assess acute postoperative pain as well as chronic postoperative pain. Parameters such as the duration of nerve blockade, the number of punctures, and any associated complications are all meticulously appraised.
Study: NCT01979796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ecig 24 mg nicotine
Description: Cigalike

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ecig 0 mg nicotine
Description: Cigalike

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine free inhalator
Description: Plastic CIG a Like
Study: NCT04895943

Intervention type: PROCEDURE
Intervention: bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
Description: bariatric endoscopy, mainly intragastric balloons, plication of the stomach too

Intervention type: PROCEDURE
Intervention: bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
Description: bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
Study: NCT05855928

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mime Therapy
Description: electrical stimulation with the MIME therapy and protocol

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PNF Technique
Description: electrical stimulation with the PNF technique with the routine physical therapy
Study: NCT06755684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befotertinib combined Bevacizumab
Description: Befotertinib combined Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Befotertinib combined platinum-based double chemotherapy
Description: Befotertinib combined platinum-based double chemotherapy
Study: NCT06751589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: 2.5 mg administered using a pre-filled injector once weekly for 4 weeks and then increase to 5 mg once weekly.
Study: NCT06760468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Arm Description: Randomly select 30 healthy and well-trained athletes aged between 20 and 30 to serve as the control group. Participants in the control group will undergo an 8-week placebo supplementation intervention. The placebo has a similar appearance and taste to the probiotic powder but does not contain active probiotic ingredients. Before the intervention begins, a comprehensive health assessment and exercise capacity test will be conducted for the participants. Blood samples will be collected for baseline biochemical marker analysis. Participants will be instructed to take the placebo once a day at the same time to ensure the consistency and standardization of the intervention. Participants will be asked to record their daily consumption, including the time of intake, any omissions, or discomfort. After the 8-week intervention, exercise capacity tests and blood sample collections will be conducted again. Comparing exercise performance and biochemical markers before and after t

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Experimental:~Arm Description: Randomly select 30 healthy and well-trained athletes aged between 20 and 30 to serve as the experimental group. Participants in the experimental group will undergo an 8-week probiotic powder supplementation intervention. The dosage of the probiotic powder is set at 1x10\^9 CFU/kg·bw·d, which means ingesting 10 billion CFU (Colony-Forming Units) of probiotics per kilogram of body weight per day. Before the intervention begins, a comprehensive health assessment and exercise capacity test will be conducted for the participants. Blood samples will be collected for baseline biochemical marker analysis. Participants will be instructed to take the probiotic powder once a day at the same time to ensure the consistency of the dosage and the standardization of the intervention. Participants will be asked to record their daily consumption, including the time of intake, any omissions, or discomfort. After the 8-week intervention, exercise ca
Study: NCT06760182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH2722 injection
Description: TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH2722 Placebo
Description: Placebo without drug substance.
Study: NCT06759636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim N01
Description: 3.0 µg/kg, subcutaneous injection, once a week. Afterwards, refer to the platelet count evaluated during the visit before the next dosing cycle: ① If the platelet count is less than 50×10\^9/L, increase by 1-2μg/kg once a week; ② If the platelet count is between 50-99×10\^9/L, increase by 1μg/kg once a week. According to platelet count and symptoms, investigators can adjust the dosage to the maximum dosage of 10μg/kg once a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Interleukin-11 (rhIL-11)
Description: 25-50μg/kg, subcutaneous injection, once a day
Study: NCT06758596

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: A capsule that contains only dextrose filler administered during the first or second laboratory visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC
Description: A capsule that contains 7.5 mg of THC as well as dextrose filler administered during the first or second laboratory visit.
Study: NCT06758856

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trimethylglycine
Description: Betaine anhydrous from sugar beets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trimethylglycine
Description: Betaine anhydrous from sugar beets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: 3 whole eggs

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Cellulose
Study: NCT06760455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPR-30221616 Injection
Description: BPR-30221616 will be administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Injection
Description: Sodium Chloride Injection will be administered by SC injection
Study: NCT06759337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Ball Group
Description: Participants are given a colored silicone stress ball (5-7 cm diameter) 5 minutes before the procedure. During the procedure, they are instructed to squeeze the ball twice after counting to 10 and repeat this until the procedure is complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand-Holding Group
Description: The researcher holds one of the participant's hands during catheter insertion and removal. The researcher's fingers are closed but not interlocked and placed gently on the participant's hand without additional movements or gloves.
Study: NCT06759909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin (DAPA)
Description: We will record all baseline characteristics (Age, sex, BMI, HR and BP), AF type, EHRA class, previous use of ADD (B blockers, Class I, III AAD), previous CV, prior cerebrovascular stroke and Co-morbidities (HTN, DM, IHD, HF, Renal impairment, peripheral arterial disease, OSAS). CHADS2Vasc score and HAS-BLEED score will be calculated. Trans-thoracic echocardiograms will be performed within 4 weeks before the rhythm control attempts to determine LA diameter and volumes and left ventricular hypertrophy and functions (EF and E/'e).~After enrollment, the patients will be treated with dapagliflozin (10 mg/d) or placebo at the time of rhythm control strategy and will continue daily treatment at the same dose till the 9 month follow-up period.
Study: NCT06759415

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise therapy was applied to individuals in both groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise therapy was applied to individuals in both groups.
Study: NCT06760364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHT102
Description: CHT 102 : MSLN UCAR-T.
Study: NCT06758752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ZAX.1400.EC.02
Description: ZAX.1400.EC.02, applied twice daily for 3 weeks after enrolment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, applied twice daily for 3 weeks after enrolment
Study: NCT06759753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleeto
Description: According to the groups, patients would be treated with Aleeto via intravenous injection, and the specific dosage of Aleeto will depend on the grouping.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleeto
Description: According to the groups, patients would be treated with Aleeto via intravenous injection, and the specific dosage of Aleeto will depend on the grouping.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with the same dosage form, odor and color as Aleeto was administered in the same way and course of treatment.
Study: NCT06760442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcrestal implant placement
Description: Delayed implant placement 2 mm subcrestally in missing mandibular posterior site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crestal implant placement
Description: Delayed implant placement equicrestally in missing mandibular posterior site.
Study: NCT06759064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid plus Sintilimab intraperitoneal injection
Description: At D-5\~D-1, drain the ascites by placing a tube in the abdominal cavity first, try to drain the ascites as much as possible according to the clinical routine, and record the amount of drainage.D1, D8, D15, D22 start the first immunocheckpoint inhibitor combined with zoledronic acid treatment, try to drain the ascites first, calculate the amount of drugs according to the patient's body weight, and then dissolve the corresponding dosage of immunocheckpoint inhibitor and zoledronic acid in 100 ml of saline and inject them into the abdominal cavity respectively, and then inject another 100 ml of saline according to the patient's tolerance. The corresponding dose of immune checkpoint inhibitor and zoledronic acid was dissolved in 100 ml of saline and injected into the abdominal cavity.
Study: NCT06758700

Intervention type: DRUG
Group type: OTHER
Intervention: Teniposide administration
Description: Teniposide administration: 60mg/m2, diluted with 500ml of 0.9% sodium chloride injection before use, intravenous infusion for more than 1 hour, for 5 consecutive days, with 21 days as one cycle of treatment.
Study: NCT06759571

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser treatment
Description: to evaluate the effect of low-level laser therapy (LLLT) bone healing when used prior and following enucleation of intra-body maxillary cystic lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser treatment
Description: to evaluate the effect of low-level laser therapy (LLLT) bone healing when used prior and following enucleation of intra-body maxillary cystic lesions
Study: NCT05850520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
Description: Intravitreally (IVT) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
Description: Intravitreally (IVT) injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Description: Intravitreally (IVT) injection.
Study: NCT06198959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
Description: Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
Description: Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
Description: Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
Description: Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.
Description: Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the FilteredFlo® Air Blanket connected to the WarmAir® Convective Warming system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system
Description: Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system.
Study: NCT05850520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham procedure will be given on visits when an active injection is not planned.
Study: NCT06198959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system
Description: Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system
Description: Evaluate cutaneous heat loss/ gain using thermal flux transducers while volunteers are covered with the Blanket Full Body blanket (CLM0101) connected to the Care Essential, Cocoon, Blower CWS5000 system.
Study: NCT05850520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham procedure will be given on visits when an active injection is not planned.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluorescein
Description: Fluorescein 100 mg/mL solution for injection is a dye that makes the retinal vessels visible during FA examinations, and as such, it will be used as an auxiliary medicinal product (AxMP) in this periodic ophthalmic examination. This medicine is for diagnostic use only. It is not used to treat any condition.
Study: NCT05987969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alena mobile application
Description: This mobile application primarily comprises CBT-based therapy for social anxiety based on the Clark and Wells model, as well as cognitive assessments, calming exercises and a community forum.
Study: NCT04567888

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Happify Teens
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study: NCT06518798

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: Participants will be instructed to follow their usual diet except for 5 days when they eat the foods in the FMD kit. The FMD consists of a blend of 100% plant based nutrients generally regarded as safe. One FMD kit provides for the replacement of the normal diet with plant products for five consecutive days. The formulation of these products was based on studies carried out at the Longevity Institute of the University of Southern California, led by Dr. Valter Longo and his collaborators over several decades of research.
Study: NCT05315180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-421286
Description: Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-421286
Description: Characterize the pharmacokinetics (PK)，safety，effcicay of BPI-421286 following administration as an oral Tablet formulation
Study: NCT06283784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yovis Capsules
Description: Subjects will assume the active treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will assume the placebo treatment for 10 consecutive days (1 capsule once daily) with a drop of water, preferably without food.
Study: NCT05463874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Self-Compassion Program
Description: The intervention consists of 8 sessions, one per week for 8 weeks, that last 1 hour and 30 minutes each. These sessions will cover a variety of mindfulness and self-compassion practices, such as dealing with difficult emotions and developing a kind inner voice.
Study: NCT05607940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood volume loss based blood transfusion
Description: Blood transfusion is indicated based on the estimated intraoperative blood loss. When intraoperative blood loss exceeds 400ml, blood transfusion begin. At the end of the operation, we ensure that the volume of blood transfusion is no greater than the anticipated blood loss.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemoglobin concentration based blood transfusion
Description: Blood transfusion is indicated based on the intraoperative hemoglobin concentration. Intraoperative blood transfusion begins when hemoglobin concentration is blow 70g/L. Intraoperative blood transfusion stops when hemoglobin concentration reaches 80g/L
Study: NCT06200987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penile vibrator
Description: In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months
Study: NCT06521957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy